Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer: Phase II southwest oncology group study S9504

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 2004-2010

  Gandara, David R ^a   Chansky, Kari ^a   Albain, Kathy S ^a   Leigh, Bryan R ^a   Gaspar, Laurie E ^a   Lara Jr , Primo N ^a   Burris, Howard ^a   Gumerlock, Paul ^a   Kuebler, J Philip ^a   Bearden III, James D ^a   Crowley, John ^a   Livingston, Robert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; TREATMENT FAILURE; ADULT; AGED; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UNITED STATES;

EID: 0038688474     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.197     Document Type: Article

References (36)

1. Edelman MJ, Gandara DR, Roach M, et al: Multi-modality therapy in stage III non-small cell lung cancer. Ann Thor Surg 61:1564-1572, 1996
2. Dillman RP, Herndon J, Seagren SL, et al: Improved survival in stage III NSCLC: Seven year follow-up of CALGB 8433. J Natl Cancer Inst 88:1210-1215, 1996
3. LeChevalier T, Arrigada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: First analysis of a randomized trial of 353 patients. J Natl Cancer Inst 83:417-423, 1991
4. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
5. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530, 1992
6. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
7. Curran W, Scott C, Langer R, et al: Phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 29:93, 2000 (abstr 303)
8. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 11:1391-1402, 1993
9. Edelman MJ, Gandara DR: Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 37:385-393, 1996
10. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390A)
11. Goldberg Z, Gaspar L, Lara R, et al: Combined modality treatment of non-small cell lung cancer, in Pass HI (ed): Lung Cancer Principles and Practice Updates. Philadelphia, PA, Lippincott, Williams, and Wilkins, 2001, pp 1-11
12. Edelman M, Gandara DR, Lau D, et al: Sequential combination chemotherapy in patients with advanced non-small cell lung carcinoma. Cancer 92:146-152, 2001
13. Gandara DR, Yokes E, Green M, et al: Activity of docetaxel in platinum-treated non-small cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol 18:131-135, 2000
14. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: Mature results of SWOG 8805. J Clin Oncol 13:1880-1892, 1995
15. Albain KS, Crowley JJ, Turrisi AT, et al: Concurrent cisplatin, etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer: A Southwest Oncology Group phase II study (S9019). J Clin Oncol 20:3454-3460, 2002
16. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Choy H, Akerley W, Safran U, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:12:2682-2686, 1994
18. Belani CP, Aisner J, Day R, et al: Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced non-small cell lung cancer: Three year follow-up. Proc Am Soc Clin Oncol 16:448a, 1997 (abstr 1608)
19. Choy H, Akerley W, Safran H, et al: Multi-institutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced inoperable non-small cell lung cancer. J Clin Oncol 16:3316-3322, 1998
20. Lau D, Leigh B, Gandara DR, et al: Twice weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small cell lung cancer: A California Cancer Consortium phase II trial. J Clin Oncol 19:442-447, 2001
21. Zinner R, Fossella F, Komaki R, et al: Phase I trial of concurrent gemcitabine (G) plus chest radiotherapy (XRT), followed by consolidation systemic chemotherapy with G plus cisplatin (CDDP), for patients with stage III and medically inoperable stage II non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18:466a, 1999 (abstr 1798)
22. Vokes EE, Herndon JE, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20:4191-4198, 2002
23. Gandara DR, Edelman M, Lara P, et al: Evolution of combined modality therapy for stage III non-small cell lung cancer. Oncology 14:35-41, 2000 (suppl)
24. Choy H, Curran WJ, Scott CB, et al: Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: A randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1160)
25. Fossella FV: Docetaxel in the treatment of non-small cell lung cancer: Review of single-agent trials. Semin Oncol 26:17-23, 1999 (suppl 16)
26. Fosella F, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
27. Gandara DR, Vokes E, Green M, et al: Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol 18:131-135, 2000
28. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
29. Blagosklonny M, Schulte TW, Nguyen P, et al: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56:1851-1854, 1996
30. Gumerlock PH, Mack PC, Manorek GH, et al: Bcl-2 phosphorylation and p27 induction as potential p53-independent mechanisms of apoptotic response to taxanes in non-small cell lung carcinoma. Proc Am Assoc Cancer Res 40:739, 1999 (abstr 4879)
31. Gandara DR, Lovato LC, Albain KS, et al: Pathological stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consolidation of docetaxel following concurrent chemoradiotherapy (SWOG 9504). Lung Cancer 29:92, 2000 (abstr 302)
32. Gaspar L, Gandara D, Chansky K, et al: Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): Patterns of failure and updated survival. Proc Am Soc Clin Oncol 20:315a, 2001 (abstr 1255)
33. Koukourakis MI, Kourousis C, Kamilaki M, et al: Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer: A phase I/II dose escalation trial. Eur J Cancer 34:838-844, 1998
34. Scagliotti GV, Manegold C, Buchholz E, et al: Randomized phase II study evaluating the feasibility of thoracic radiotherapy with or without weekly docetaxel (Taxotere) following induction chemotherapy with cisplatin (DDP) and docetaxel in unresectable stage IIIA/B non-small cell lung cancer. Proc Am Soc Clin Oncol 21:320a, 2002 (abstr 1279)
35. Schwarzenberger PO, Barron S, Wynn R, et al: Docetaxel chemosensitization with once weekly, hypofractionated thoracic radiation. Proc Am Soc Clin Oncol 21:211 b, 2002 (abstr 2662)
36. Thirion P, McGibney C, Holmberg O, et al: 3-Dimensional conformal radiation therapy (3DCRT) permits radiobiological dose escalation for non-small-cell lung cancer (NSCLC): Preliminary results of a phase I/II Trial. Proc Am Soc Clin Oncol 20:344a, 2001 (abstr 1373)